{"id":55166,"date":"2023-03-24T07:03:11","date_gmt":"2023-03-24T06:03:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/"},"modified":"2023-03-24T07:03:11","modified_gmt":"2023-03-24T06:03:11","slug":"benevolentai-announces-publication-of-convening-notice-for-agm","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/","title":{"rendered":"BenevolentAI Announces Publication of Convening Notice for AGM"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

\nBenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces the publication of the convening notice for its Annual General Meeting which will be held on 4 May 2023 at 14:00 CEST at 5 place Winston Churchill, L-1340 Luxembourg (the \u201cAGM\u201d).\n<\/p>\n

\nThe convening notice, Annual Report and Accounts for the financial year ended 31 December 2022, the proxy form and any other meeting documentation are available on the Company\u2019s website (www.benevolent.com\/investors\/general-meetings\/<\/a>) and at the Company\u2019s registered office.\n<\/p>\n

\nThe shareholders entitled to participate and vote at the AGM will be those who are shareholders on the record date of 20 April 2023 at 24:00 (midnight) CEST.\n<\/p>\n

\nAbout BenevolentAI<\/b>\n<\/p>\n

\nBenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform\u2122 powers the Company\u2019s in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEnquiries: <\/b>\n<\/p>\n

\nInvestors:<\/b>
Fleur Wood \u2013 VP Investor Relations
\n
fleur.wood@benevolent.ai<\/a>
investors@benevolent.ai<\/a>
T: +44(0) 203 781 9360\n<\/p>\n

\nCompany Secretary:<\/b>
Judit Molnar \u2013 Deputy Company Secretary
\n
cosec@benevolent.ai<\/a>
T: +44(0) 203 781 9360\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–Regulatory News: BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces the publication of the convening notice for its Annual General Meeting which will be held on 4 May 2023 at 14:00 CEST at 5 place Winston Churchill, L-1340 Luxembourg (the \u201cAGM\u201d). The convening notice, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55166","6":"format-standard","7":"category-industry"},"yoast_head":"\nBenevolentAI Announces Publication of Convening Notice for AGM - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BenevolentAI Announces Publication of Convening Notice for AGM - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–Regulatory News: BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces the publication of the convening notice for its Annual General Meeting which will be held on 4 May 2023 at 14:00 CEST at 5 place Winston Churchill, L-1340 Luxembourg (the \u201cAGM\u201d). The convening notice, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-24T06:03:11+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BenevolentAI Announces Publication of Convening Notice for AGM\",\"datePublished\":\"2023-03-24T06:03:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/\"},\"wordCount\":250,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/\",\"name\":\"BenevolentAI Announces Publication of Convening Notice for AGM - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-24T06:03:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-announces-publication-of-convening-notice-for-agm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BenevolentAI Announces Publication of Convening Notice for AGM\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BenevolentAI Announces Publication of Convening Notice for AGM - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/","og_locale":"en_US","og_type":"article","og_title":"BenevolentAI Announces Publication of Convening Notice for AGM - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–Regulatory News: BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces the publication of the convening notice for its Annual General Meeting which will be held on 4 May 2023 at 14:00 CEST at 5 place Winston Churchill, L-1340 Luxembourg (the \u201cAGM\u201d). The convening notice, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-24T06:03:11+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BenevolentAI Announces Publication of Convening Notice for AGM","datePublished":"2023-03-24T06:03:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/"},"wordCount":250,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/","url":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/","name":"BenevolentAI Announces Publication of Convening Notice for AGM - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-24T06:03:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-announces-publication-of-convening-notice-for-agm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BenevolentAI Announces Publication of Convening Notice for AGM"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55166"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55166\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}